{"id":3152,"date":"2018-09-05T16:56:50","date_gmt":"2018-09-05T11:26:50","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3152"},"modified":"2021-07-24T12:57:03","modified_gmt":"2021-07-24T07:27:03","slug":"snippet-hiv","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/snippet-hiv","title":{"rendered":"SNIPPET"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Merck &amp; Company<\/strong> virology business is flickering, after announcing two of its new <a href=\"https:\/\/www.delveinsight.com\/report-store\/hiv-attachment-inhibitor-pipeline-insight\">HIV <\/a>medications that bagged approval from the <strong>Food and Drug Administration (FDA)<\/strong>. The oral medications, <strong>Pifeltro and Delstrigo<\/strong>, are taken once-daily with or without food for adult HIV-1 patients, who have never received\u00a0antiretroviral treatment. In Pifeltro, <strong>doravirine<\/strong> is the only active ingredient drug, while Delstrigo pairs that drug in a fixed-dose combination tablet with <strong>tenofovir disoproxil<\/strong> and <strong>lamivudine<\/strong>. In the Phase 3 DRIVE-AHEAD study, Delstrigo showed non-inferiority to Atripla of Gilead Sciences. In the DRIVE-FORWARD study, Pifeltro showed non-inferiority to Prezista of Johnson &amp; Johnson plus 100 mg of\u00a0ritonavir. Both treatments in DRIVE-FORWARD were administered in combination with either Epzicom\/Kivexa or Truvada of Gilead.<\/p>\n<p style=\"text-align: justify;\">\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Company virology business is flickering, after announcing two of its new HIV medications that bagged approval from the Food and Drug Administration (FDA). The oral medications, Pifeltro and Delstrigo, are taken once-daily with or without food for adult HIV-1 patients, who have never received\u00a0antiretroviral treatment. In Pifeltro, doravirine is the only active ingredient [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3097,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[1743,1746,704,297,1747,1745,1744,1748,586],"industry":[17225],"therapeutic_areas":[17240,17231],"class_list":["post-3152","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-delstrigo","tag-doravirine","tag-fda","tag-hiv","tag-lamivudine","tag-merck-company","tag-pifeltro","tag-tenofovir-disoproxil","tag-u-s-food-and-drug-administration","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Snippet | HIV | 5\/09\/18 | - DelveInsight Business Research LLP<\/title>\n<meta name=\"description\" content=\"Merck &amp; Company virology business is flickering, after announcing two of its new HIV medications that bagged approval from the.....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/snippet-hiv\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snippet | HIV | 5\/09\/18 | - DelveInsight Business Research LLP\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Company virology business is flickering, after announcing two of its new HIV medications that bagged approval from the.....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/snippet-hiv\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-05T11:26:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Snippet | HIV | 5\/09\/18 | - DelveInsight Business Research LLP","description":"Merck & Company virology business is flickering, after announcing two of its new HIV medications that bagged approval from the.....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/snippet-hiv","og_locale":"en_US","og_type":"article","og_title":"Snippet | HIV | 5\/09\/18 | - DelveInsight Business Research LLP","og_description":"Merck & Company virology business is flickering, after announcing two of its new HIV medications that bagged approval from the.....","og_url":"https:\/\/www.delveinsight.com\/blog\/snippet-hiv","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-09-05T11:26:50+00:00","article_modified_time":"2021-07-24T07:27:03+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-hiv","url":"https:\/\/www.delveinsight.com\/blog\/snippet-hiv","name":"Snippet | HIV | 5\/09\/18 | - DelveInsight Business Research LLP","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-hiv#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-hiv#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer.jpg","datePublished":"2018-09-05T11:26:50+00:00","dateModified":"2021-07-24T07:27:03+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Merck & Company virology business is flickering, after announcing two of its new HIV medications that bagged approval from the.....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/snippet-hiv"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-hiv#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer.jpg","width":640,"height":400,"caption":"Cancer"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer-300x188.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Delstrigo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">doravirine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">HIV<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">lamivudine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Merck &amp; Company<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Pifeltro<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">tenofovir disoproxil<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">U.S. Food and Drug Administration<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Delstrigo<\/span>","<span class=\"advgb-post-tax-term\">doravirine<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">HIV<\/span>","<span class=\"advgb-post-tax-term\">lamivudine<\/span>","<span class=\"advgb-post-tax-term\">Merck &amp; Company<\/span>","<span class=\"advgb-post-tax-term\">Pifeltro<\/span>","<span class=\"advgb-post-tax-term\">tenofovir disoproxil<\/span>","<span class=\"advgb-post-tax-term\">U.S. Food and Drug Administration<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 5, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 5, 2018 4:56 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3152"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3152\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3097"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3152"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3152"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}